Latest news

BCNA News 21 Aug 2017

No PBS listing for new breast cancer drugs ribociclib and palbociclib

The Pharmaceutical Benefits Advisory Committee* (PBAC) has recommended to the Australian Government that the new breast cancer drug ribociclib (Kisqali) not be listed on the Pharmaceutical Benefits Scheme (PBS). This follows its decision earlier this year to not recommend palbociclib (Ibrance) be added to the PBS. Read more